Allogene Therapeutics (ALLO) vs Autolus Therapeutics (AUTL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Autolus Therapeutics (AUTL) has outperformed Allogene Therapeutics (ALLO) over the past year, losing 26.2% versus a loss of 49.0%. Over five years, AUTL leads with a -85.5% price change compared with -96.5% for ALLO. Autolus Therapeutics is the larger company by market cap ($241.7 million vs $217.5 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALLO | AUTL |
|---|---|---|
| Share price | $0.6277 | $0.9073 |
| Market cap | $217.48M | $241.65M |
| 1-day change | -5.88% | -7.38% |
| YTD return | -54.18% | -54.41% |
| 1-year return | -48.97% | -26.24% |
| 5-year return | -96.51% | -85.51% |
| EPS (TTM) | $-0.61 | $-0.96 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $0 | $75.39M |
| Revenue growth (YoY) | -100.00% | +644.94% |
| Net income (latest FY) | $-190.89M | $-287.53M |
| Gross margin | — | -27.83% |
| Operating margin | — | -358.87% |
| Net margin | — | -381.40% |
| 52-week high | $4.46 | $2.58 |
| 52-week low | $0.6192 | $0.896 |
| Distance from 52-week high | -85.93% | -64.83% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +1333.81% | +821.42% |
| Average volume | 7.69M | 2.07M |
| Shares outstanding | 346.47M | 266.34M |
| Employees | 150 | 752 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- AUTL has outperformed ALLO by 22.7 percentage points over the past year.
- Autolus Therapeutics grew revenue faster in its latest fiscal year (+644.94% vs -100.00%).
About Allogene Therapeutics
ALLO stock →Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 150 employees
About Autolus Therapeutics
AUTL stock →Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in the United Kingdom and internationally. The company offers AUCATZYL, a gene therapy product consisting of autologous T cells that are transduced with a lentiviral vector to express a novel anti-CD19 chimeric antigen receptor.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 752 employees
ALLO vs AUTL FAQ
Which is bigger, Allogene Therapeutics or Autolus Therapeutics?
Autolus Therapeutics (AUTL) is larger, with a market capitalization of $241.65M compared with $217.48M for Allogene Therapeutics (ALLO).
Which stock has performed better over the past year, ALLO or AUTL?
AUTL returned -26.24% over the past 12 months, compared with -48.97% for ALLO (price return, excluding dividends). Past performance does not predict future results.
Are Allogene Therapeutics and Autolus Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.